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Abstract 
BACKGROUD: Sunitinib and Pazopanib are two metastatic renal cell carcinoma (MRCC) 
treatment alternatives, however the health system in Chile does not consider coverage for 
any. The cost-effectiveness versus relevant comparator was assessed to support evidence-
based decision making. 
METHODS: A four health states Markov model was built: first, second line treatments, BSC 
and death. Benefits were measured in QALYs and efficacy estimates were obtained from an 
indirect treatment comparison. A 10-year time horizon and a 3% undifferentiated discount 
rate were considered. Deterministic and probabilistic sensitivity analyses were performed. 
RESULTS: The costs of treating MRCC with Sunitinib were higher than Pazopanib and BSC. 
When comparing Sunitinib versus Pazopanib, the incremental benefit is small favoring 
Sunitinib (0.03 QALYs). The base case scenario shows an average ICER of PA versus BSC of 
US$62,327.11/QALY and of US$85,885/QALY for Sunitinib versus Pazopanib. The ICER was 
most sensitive to the OS relative to BSC, where evidence was associated to important bias. 
CONCLUSIONS: Sunitinib or Pazopanib can be considered cost-effective if a 3 GDP per-capita 
threshold is assumed. The decision between SU or PA is highly sensitive to the price of the 
drugs, rather than the outcomes. Therefore, the decision might be made based on cost-
minimization exercise. 
 
Keywords Health Technology Assessment, Cost-effectiveness, Renal cell carcinoma, Sunitinib, 
Receptor tyrosine kinase inhibitors, Pazopanib. 
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1 Introduction 
Renal cell carcinoma (RCC) is the most common type of kidney cancer accounting for 
approximately 90% of the total renal cancers. It represents 2-3% of all cancers with an 
incidence of 4.4 per 100,000 habitants, which is even greater in developed countries[1-3]. It is 
associated with a mortality rate of 3.1 per 100,000 habitants, which also increases 
exponentially in people over 50 years[3]. The most relevant associated risk factors are 
tobacco consumption, obesity and hypertension[4-6]. In Chile, RCC has an incidence of six per 
100,000 habitants and is more commonly diagnosed in men at an age ranging between 60 and 
70 years[3,7].  
Patients with stage I RCC have a 5-year survival rate between 80 to 95%, stage II 80%, stage 
III 60% and stage IV (patients with metastasis - MRCC) less than 10% with a median overall 
survival of 10 to 15 months[8]. Furthermore, nearly 30% of patients have metastases at 
diagnosis, and 40% of patients with localized tumor will develop metastases at some point of 
their disease, mainly lung, bone, liver or brain[9].  
Prior to the approval of targeted therapies, interferon alpha (IFNa) was used as first-line 
treatment for MRCC. However, it showed a limited effectiveness (10-15%) and was associated 
with high rate of discontinuation due to adverse events[10]. High-dose Interleukin-2 (IL-2) 
showed an overall response rate of 15% and 1% probability of death due to toxicity. Hence, its 
use was limited to young patients with good performance status and who had limited 
metastasis[8,11,12]. Vascular endothelial growth factor (VEGF) inhibitors such as 
Bevacizumab (BE) associated with IFNα, Sorafenib (SO), Sunitinib (SU) and Pazopanib (PA) 
have shown improved effectiveness compared with former treatments[11]. Currently, based 
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on available experience, SU and PA are the most accepted treatments and considered the 
standard of care in most countries.  
In Chile, SU and PA were approved by the regulatory agency as first-line treatments for MRCC 
in 2006 and 2013 respectively. The evidence for SU supporting this approval, comes from two 
main Phase III randomized controlled trials (RCT). The first assessed the efficacy, safety and 
overall survival (OS) of SU compared to IFNα in patients with MRCC who had no prior 
treatment[13]. The results showed a significantly higher PFS in the group of SU with a HR of 
0.42 (95% CI 0.32 - 0.54; p<0.001) and objective response rate of 31% for SU and 6% for 
IFNα. The second study showed the updated OS results with a non-statistically significant HR 
of 0.821 (95% CI 0.673 - 1.001; p=0.051)[14]. On the other hand, PA was assessed in two 
studies that compared it with placebo (PL) in patients with MRCC with intermediate or 
favorable prognosis[15,16]. The reported time to progression reached 9.2 and 4.2 months 
respectively (HR 0.46, 95% CI 0.34 - 0.62; p<0.0001). The overall response rate was 30% for 
PA and 3% for PL, with a median response duration of 58.7 weeks. Finally, the efficacy PA 
versus SU was directly compared in a randomized non-inferiority clinical trial, showing non-
inferiority of PA compared to SU either for PFS (HR 1.05 95% CI 0.9 - 1.22) or OS (HR 0.91 
95% CI 0.76 - 1.08; p=0.28)[17]. This study also claimed that PA had a better safety profile 
and health-related quality-of-life, but a higher proportion of treatment discontinuation due to 
adverse events (24% vs 20%)[17]. 
Currently, the public health system in Chile does not reimburse any targeted therapy to 
patients with MRCC who are currently only managed with palliative care.  Moreover, there are 
no renal cancer clinical guidelines or an established treatment protocol available to guide the 
management of these patients. However, most international clinical guidelines and Health 
Technology Assessment (HTA) reports have recommended the use of BE/IFNα or PA as first-
line treatment in patients with MRCC with favorable or moderate prognosis and SU as first-
Ac
ce
pte
d M
an
us
cri
pt
5 
 
line treatment for any histological type of MRCC[1,18,19]. In this context, the question 
whether to fund SU or PA or both becomes extremely relevant. In order to inform this 
decision, we performed a cost-effectiveness analysis of SU versus PA and BSC (the current 
practice in Chile) as first-line treatment of MRCC from the perspective of the Chilean public 
health care system.  
2 Patients and Methods 
2.1 Decision Model 
A time-dependent Markov model was used consisting of four health states: (1) patients 
receiving first-line treatment, (2) patients receiving second-line treatment, (3) patients 
receiving best supportive care (BSC) and (4) specific-cause death (Figure 1). A hypothetical 
cohort of MRCC patients was simulated and simultaneously treated with either SU, PA or BSC. 
It was assumed that BSC was equivalent to PL in terms of OS and PFS. The model assumed 
that patients received first-line treatment until disease progression or death. Patients who 
progressed after first-line treatment received second-line treatment, BSC or die. Similarly, 
patients receiving second-line treatment remained in that state until disease progression 
(BSC) or death. Patients that progress remain in this state until death. The model was 
implemented in Excel®, including a half cycle correction. 
Figure 1 here 
2.2 Study Perspective and discount rate. 
The study was conducted from the perspective of the Chilean public health care system and 
the costs and benefits were discounted at an annual rate of 3% as suggested in the Chilean 
economic evaluations guideline[20]. A deterministic sensitivity analysis was also performed 
considering 0% and 6% rates.   
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2.3 Treatment Effect 
Because there are no "head-to-head" studies comparing targeted therapy (SU or PA) versus 
the current practice in Chile, which is BSC, as first-line treatment for MRCC, we conducted a 
literature search that included all possible treatment alternatives to implement a mixed 
treatment comparison (MTC). This methodology allows the estimation of a treatment effect 
between comparators that have not been previously compared in head-to-head trials.  Efficacy 
was reported based on the proportion of patients who did not progress (PFS_HR) or if 
progressed, did not die (OS_HR). The MTC was implemented in Winbugs® version 1.4. 
A total of 12 head-to-head studies assessing seven possible MRCC treatments were identified: 
IFNα, PA, Temsirolimus (TEM), BE/IFNα, SO and PL (for the purpose of this study assumed 
equivalent to BSC). Two studies were excluded because the study population did not share the 
same baseline characteristics relative to the SU study, a critical aspect to conduct MTC. First, 
the study by Hudes et al that compared TEM with IFNα and the combination of both, 
considered a patient population with a more unfavorable risk profile (MSKCC ≥3)[21]. Second, 
the study that compared SO vs PL evaluated previously treated patients (IL-2/IFNα as first 
line of treatment)[22]. All the included studies were phase III RCTs. According to data 
availability, it was possible to construct the network of comparators for PFS and OS as shown 
in Figure 2-A and Figure 2-B respectively.  
Figure 2-A and 2-B here 
2.4 Survival Analysis 
Regression coefficients obtained from individual patient data (IPD) were provided from the 
SU clinical trials which reported efficacy up to 36 weeks[13,14]. The long-term treatment 
effect was modelled by adjusting a parametric distribution to the observed Kaplan Meier 
assuming the proportional hazards assumption holds. The Weibull distribution produced the 
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best goodness of fit among several tested parametric functions[23]. The probability of 
progressing from first-line treatment was obtained from the difference between the 
probability of non-progression, given by PFS, and the probability of death, given by OS.  
2.5 Costs 
Costs were measured in 2014 Chilean pesos adjusted by consumer price index and converted 
into US dollars using average 2014 exchange rate (1 USD = 654.07 CLP)[24]. The main sources 
of information for the identification of resources were: (i) the Chilean cost study used to 
estimate the per patient premium for the national health benefit plan; (ii) the 2014 public 
payer (FONASA) tariffs available for a limited list of health services/resources; and (iii) the 
ESMO clinical practice guidelines for the management of RCC[25,26]. This information was 
supplemented by other international literature when required. The price of treatments were 
requested to the national procurement entity (CENABAST) who provided the average 2014 
price for each medication. 
2.6 Utility values 
Health related quality of life (HRQoL) estimates were obtained from patient data collected 
from two SU clinical trials[17,27]. These studies measured HRQoL using the EQ-5D and valued 
using the British tariff. As the trial did not consider PA, it was assumed that the quality of life 
of these patients corresponded to the weighted average utility of patients receiving SU during 
each cycle of 6 weeks (4 weeks on treatment plus 2 weeks off treatment). In order to assess 
possible uncertainties around these point estimates, a review of the literature was conducted 
to obtain additional parameters which were later tested in the deterministic sensitivity 
analysis.  
2.7 Sensitivity Analysis 
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We conducted a deterministic sensitivity analysis with variations of ±30% relative to the 
point estimate in all relevant parameters. A probabilistic sensitivity analysis was also 
performed to characterize second order uncertainty.  
2.8 Baseline Scenario 
For the economic analysis, the base case was constructed based on the recommendations 
established in the economic evaluation guideline[20,25]. Based on clinical experts` opinions, 
this study assumed that after progressing from first-line treatment, patients could only 
receive BSC. The main arguments supporting this assumption was that the net benefit 
associated to second line treatments was still unclear. In addition, the current relevant 
question in Chile refers to first line. A scenario analysis was conducted to assess the effect on 
the results of transiting through a second line health state. Survival curves were constructed 
using the regression parameters obtained from the study that compared SU versus IFN. For 
extrapolation beyond trial duration, a 10-year time-horizon was considered. Table 1 
summarizes the baseline scenario assumptions. 
Table 1. Base line scenario: model input parameters and assumptions  
Parameter Base case Assumption/ Comment 
Discount rate 3% 
Recommended in the local 
economic evaluation 
guideline[20].  
2nd line probability  0% Experts input. 
Regression coefficients from 
IPD to build survival curves  SU vs IFN  
Available data provided in the 
model. 
Survival extrapolation Weibull As per visual inspection and expert’s opinion.  
HR PA versus PL 0.43 (95% CI 0.215 – 1.388; p=0.172) 
Adjusted by cross over 
(RPSFT)[16] 
Time Horizon 10 years Experts input 
SU posology  4 x 2 (4 weeks on treatment followed by 2 weeks off treatment) Approved posology in Chile[29]  
PA posology 800 mg daily until progression Approved posology in Chile[30] 
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Comparators - PA - BSC Experts input 
Abbreviations: BSC: best supportive care; HR: hazard ratio; IFN: interferon; IPD: individual patient 
data; mg; milligrams; N/A: not applicable; PA: pazopanib; PL: placebo; RPSFT: Rank Preserving 
Structural Failure Time; SU: sunitinib.  
2.9 Second line treatment scenario 
A scenario analysis was conducted assuming 50% of patients were suitable to receive 
treatment with Axitinib (AX). Based on published data, it was assumed that OS was equivalent 
to the survival curve of patients receiving IFNα as first-line treatment. This assumption was 
supported by the visual inspection of the curves of the study that compared AX versus SO and 
the study that compared SU versus IFNα as well as expert opinion[13,14,31]. 
3 Results 
3.1 Treatment effect – Mixed Treatment Comparison 
A detailed analysis of each study was conducted to identify the best point estimate to be 
included in the MTC. A relevant aspect to highlight regarding the study comparing SU vs IFNα  
was the fact that some patients who initially received IFNα, changed to SU (cross-over)[14]. 
For this reason, an adjusted by cross-over (0.808; 95% CI 0.661-0.987; p=0.036), intention to 
treat (ITT) (OS HR: 0.821; 95% CI 0.673 – 1.001; p=0.051) and a post hoc analysis (0.647; 
95% CI: 0.483-0.870; p=0.003) OS HR were reported. The latter estimate only included 
patients who did not receive SU after the study ended. Finally, the MTC was conducted 
maintaining a conservative approach by using the ITT HR as the OS treatment effect.  
A critical aspect was also identified in the study that compared PA versus PL, where the ITT 
analysis for OS did not show significant differences (HR: 0.91; 95% CI 0.7-1.16; p=0.224)[16]. 
This study considered treatment naïve and cytokine pre-treated patients. This was partly 
explained by the cross-over of 54% of placebo patients to PA after disease progression was 
established through an open (non-blind) study extension. An adjusted HR using the RPSFT 
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(Rank preserving structural failure time) methodology was reported (OS HR: 0.432; 95%CI 
0.215-1.388; p=0.172). This methodology was considered adequate based on 
recommendations that suggest to use this approach when there is a high proportion of cross-
over (>50%)[32,33]. Additionally, it was considered inappropriate to use the adjusted HR in 
the naive population (OS HR: 0.31; 95% CI 0.073 - 1.715; p= not reported) due to the great 
uncertainty observed (limited number of patients analysed) and possible risk of treatment 
effect overestimation.  
Finally, despite statistically significant differences were not found in the HR ratio reported in 
the non-inferiority study of PA vs SU, the trial met good standards for internal validity. Hence, 
the treatment effect estimate was considered a useful parameter from the perspective of an 
economic evaluation (OS HR 0.91; 95% CI: 0.76 - 1.08: p=0.28)[17]. The main difference 
between non-inferiority and superiority trials relates to the statistical power and confidence, 
which affects statistical inference. Therefore, because we propagated second order 
uncertainty in a Bayesian statistical framework and we focused on the a-posteriori expected 
outcomes, those concerns for statistical inference were considered no longer relevant for the 
cost-effectiveness results. Instead, we should focus our interpretative efforts on the results of 
the probabilistic sensitivity analysis. 
The results of the MTC for PFS and OS are presented in Table 2. This table shows the results 
comparing each treatment versus the baseline IFNα curve. 
Table 2. Results of the indirect treatment comparison for the PFS and OS hazard ratio of all 
possible MRCC treatments.  
Treatment  Comparator HR BCI 95% 
Number of 
simulations 
Progression Free Survival (PFS) 
SU vs IFNα 0.543 0.45 0.648 5,000 
BE/IFNα vs IFNα 0.6761 0.60 0.758 5,000 
PA vs IFNα 0.572 0.45 0.717 5,000 
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BSC vs IFNα 1.459 0.90 2.246 5,000 
Overall Survival (OS) 
SU vs IFNα 0.8251 0.6758 1.009 5,000 
BE/IFNα vs IFNα 0.8605 0.5706 0.974 5,000 
PA vs IFNα 0.7525 0.6485 4.555 5,000 
BSC vs IFNα 1.953 0.6758 1.009 5,000 
Abbreviations: BE/IFNα: bevacizumab plus interferon alpha; BCI: Bayesian credibility interval; BSC: 
best supportive care; HR: hazard ratio, IFNα: interferon alpha; PA: pazopanib; SU: sunitinib; vs: versus. 
3.2 Costs 
For each health state, resources were identified, measured and valued within three main 
categories: (1) MRCC pharmacological treatment; (2) management of adverse events; and (3) 
disease monitoring/follow-up. It should be noted that adverse events were obtained from the 
pivotal trials of each possible comparator. Subsequently, to estimate the expected cost per 
event, a basket of resources was constructed considering all possible alternatives of 
management. It was assumed that in the presence of a grade 3 or 4 adverse events, the patient 
would consult to an emergency department. For the rest of the events (grade 1 and 2), it was 
assumed they were all managed on an outpatient basis and according to the indications 
during follow-up with the oncologist. The same number of follow-up visits were considered 
for each patient regardless the treatment, because the aim was to assess treatment response, 
disease progression and monitoring adverse effects. The baskets were built based on what 
was suggested in clinical guidelines and validated with oncologists according to the resources 
currently available in the Chilean public health system. The summary of costs per cycle are 
shown in Table 3. 
Table 3. Expected cost per cycle (6 weeks) and category for each "First line" and "second line" 
treatment in 2015 US dollars  
Cost categories 
1st line de treatment Treatment after 1st line failure
Sunitinib Pazopanib Axitinib BSC 
Pharmacological 
treatment $2.973,80 $2.969,87 $7.926,75  
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Adverse Events $165,96 $124,33 $61,55 
Follow Up $193,19 $193,19 $193,19 
BSC management1 $434,26
Abbreviations: BSC: best supportive care.  
NOTE: 1The average expected cost considers laboratory tests, mental health, medical procedures, 
hospitalization, images, medical supplies and medical visits with a specialist. 
3.3 Cost-effectiveness results 
The average total cost of treating a patient diagnosed with MRCC with SU is greater than 
treating the same patient with PA, which is higher than the cost of only providing BSC 
($45,786.29; $43,255.05; and $5,091.97 respectively). It should be noted that minimal 
variations in drug prices produce important changes in the results which is also reflected in 
the small total incremental cost between SU and PA ($2,531.24). Similarly, the additional cost 
of treating a patient with PA instead of BSC is $38,163.08, which is mainly explained by the 
price of the drug. It should be noted that less than 5% of the total cost involves the use of 
resources for the management of adverse events. The highest total cost associated with SU is 
explained by the fact that a smaller proportion of patients progress per cycle, thus increasing 
the period of treatment. This is reflected in an increase in the total expected cost of BSC in 
patients treated with PA.  
A patient treated with SU accumulates in 10 years, on average, 1.399 QALYs and a patient 
treated with PA 1.37 QALYs leading to an incremental benefit of SU vs PA of only 0.03 QALY. 
The average ICER when comparing PA versus BSC is $62,327.11/QALY and SU versus PA 
$85,885.22/QALY (see Table 4). Both ICERs are on the efficiency frontier and above the 
suggested cost-effectiveness threshold in Chile of 1 GDP per capita (estimated at $18,346.66).  
The baseline scenario showed that the incremental health benefit is low when comparing PA 
versus SU (0.03 QALYs). Hence, it is expected that any variation of the price of the drug will 
significantly change the ICER. For this reason, the cost effectiveness results are presented 
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varying the maximum price of SU and PA to 75%, 50% and 25% in relative terms (see Table 
4). At all evaluated prices, the average ICER is above the threshold of 1 GDP per capita and at 
the lowest evaluated price (75% reduction) the ICER of PA vs BSC and SU vs PA reaches 
$22,324.88 and $40,664.05 per additional QALY respectively. 
Table 4. Cost effectiveness results: incremental analysis of sunitinib versus pazopanib and 
BSC as first line treatments for the base case and price reduction scenarios. 
Analysis TX Total cost Total QALY Inc Cost. QALY Inc. 
ICER 
($/QALY) 
Base Case 
BSC $5,091.97 0.757  
PA $43,255.05 1.370 $38,163.08 0.61 $62,327.11
SU $45,786.29 1.399 $2,501.23 0.03 $85,885.22 
25% 
reduction 
BSC $5,091.97 0.757  
PA $35,090.56 1.370 $29,998.59 0.61 $48.993.04 
SU $31,177.54 1.399 $2,086.98 0.03 $70,811.49 
50% 
reduction 
BSC $5,091.97 0.757  
PA $26,926.06 1.370 $21,834.09 0.61 $35,658.96 
SU $28,568.78 1.399 $1,642.72 0.03 $55,737.77 
75% 
reduction 
BSC $5,091.97 0.757  
PA $18,761.57 1.370 $13,669.60 0.61 $22,324.88 
SU $19,960.03 1.399 $1,198.46 0.03 $40,664.04 
Abbreviations: BSC: best supportive care; ICER: incremental cost effectiveness ratio; Inc: incremental; 
PA: pazopanib, QALY: quality adjusted life years; SU: sunitinib; TX: treatment.  
NOTE: treatment price reduction were relative to the published list price. 
3.3.1 Scenario Analysis 
The scenario analysis (Table 5) showed the impact on the results when 50% of the patients 
treated with SU and PA were treated with AX as second line upon progression. The estimated 
total expected cost of treating with SU and PA increased to $69,400.21 and $67,936.89, 
respectively and health benefits to 1.51 and 1.49 respectively. It should be noted that the 
incremental benefit of SU versus PA is lower compared to the baseline scenario (0.024 QALYs) 
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leading to a higher ICER. The incremental analysis shows extended dominance of SU versus 
PA, thus resulting in an ICER of $85,446.97/QALY when comparing SU versus BSC.  
Table 5. Cost effectiveness results: scenario analysis assuming 50% of patients’ treated with 
SU/PA were given second line treatment.  
TX Total cost Total QALY Inc Cost. QALY Inc. ICER ($/QALY) 
BSC $5,091.97 0.757
PA $67,936.89 1.486 $62,844.92 0.73 $86,307.33 
SU $69,400.21 1.510 $1,463.32 0.02 $59,831.92 
Abbreviations: BSC: best supportive care; ICER: incremental cost effectiveness ratio; Inc: incremental; 
TX: treatment; PA: pazopanib; QALY: quality adjusted life years; SU: sunitinib.  
3.3.2 Deterministic sensitivity analysis 
The greatest variation of the ICER was observed when varying the OS HR based on the 95% 
BCI of SU versus BSC reported from the MTC (95% BCI 0.6485 to 4.555). The large amplitude 
of the interval reveals the great uncertainty associated with this parameter. When assuming 
the lowest value, the ICER was reduced to $34,518.97/QALY and when increased to the 
highest, the ICER reaches an estimated value of $213,676.82/QALY. Other parameters that 
impacted the results were: the utility of SU while on treatment, the utility of BSC, the 
probability of receiving second line treatment, and the utility of SU while off treatment.  
As the difference is so minimal in terms of total accrued QALYs when comparing SU versus PA, 
it was reasonable to assess a different scenario in which the utility of both interventions was 
varied. The results showed that a relative 10% reduction in the utility of PA, decreased the 
ICER of SU vs PA to $4,348.79/QALY (incremental QALYs increased from 0.03 to 0.08). 
Similarly, if the utility of PA increases 10% in relative terms, the strategy became dominant. 
Hence, the ICER was very sensitive to minimal variations in the quality of life of one 
intervention versus another. 
3.3.3 Probabilistic sensitivity analysis 
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A probabilistic sensitivity analysis was conducted using the four above mentioned prices. 
These were graphically represented in an incremental cost effectiveness plane (Figure 3-A 
and 3-B) where each point represents one simulation and the black and red line, the 1 and 3 
GDP per capita threshold respectively. The set of ICERs distinguished in the plane come from 
the comparison between SU vs BSC and PA vs SU assuming the base case (Figure 3-A). 
Similarly, Figure 3-B shows the simulation results when the price of SU and PA was dropped 
25%.  
Another way to represent the uncertainty of the results is through an acceptability curve 
(Figure 4-A and Figure 4-B). The probability of cost effectiveness at a 1 GDP per capita 
threshold was zero for the first three scenarios (baseline, 75% and 50%). When the price of 
both strategies was reduced by 75%, the probability of cost effectiveness reached 
approximately 40%. This probability increased to more than 80% when the price of SU and 
PA was dropped at least 25% considering a 3 GDP per capita threshold.  
Here Figure 3-A and 3-B 
Here Figure 4-A and 4-B 
4 Discussion 
The treatment and management of patients with MRCC until 2006 was very limited. However, 
in recent years, the development of new targeted drugs has shown to positively change the 
prognosis of these patients. Among them, SU and PA are the most recognized alternatives for 
the management of this disease. These alternatives offer patients more health in terms of 
years of life and quality of life, but have a very high associated cost that limits their use. The 
latter has motivated health systems to produce local evidence to answer the question whether 
or not is worth paying for this new but more expensive intervention. The objective of this 
study was to determine the cost-effectiveness of SU compared to PA and BSC from the 
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perspective of the Chilean public health system in order to provide evidence to support 
decision making regarding the potential allocation of resources to finance this new 
therapeutic alternative.  
SU and PA demonstrated important effects on PFS and quality of life of patients with MRCC. 
However, the results of this study showed that when comparing SU or PA vs BSC, considered 
the standard of care in Chile, the incremental cost of the new strategy was very high. This 
results in ICERs that are above the suggested cost-effectiveness threshold of 1 GDP per capita. 
On the other hand, when comparing SU vs PA, the expected incremental health benefit 
measured as QALYs, was very small favoring SU on average. However, the associated 
uncertainty around the utility estimates is large and can lead to opposite results where PA 
could be more effective than SU. From a clinical point of view, the evidence does not allow to 
affirm that one drug is more effective than the other, being the price is a determinant of cost-
effectiveness. 
Our work extends to other economic evaluations conducted in different settings (mainly high-
income countries) and assessing different treatment alternatives (SU, PA, IFNα, BEV/IFNα, 
TEM and SO) considering first and/or second line treatment of MRCC. Although most studies 
were cost effectiveness/utility, systematic reviews (4), cost minimization (1), cost analysis (1) 
and HTA related reports (3) were also found. Since PA became available, five cost-
effectiveness studies comparing it with SU have been also conducted for different settings[34-
37] with one utilizing real world data[38]. All those trial based studies concluded PA was cost-
effective compared to SU. In particular, one of these studies was later discussed by other 
authors who raised important limitations to the reported results that established PA as a 
dominant alternative compared to SU[39]. Their arguments were mainly focused on the utility 
estimates and sources of data used to conduct the survival analysis. In our study, we have 
further discussed these issues and the possible impact these limitations may have on study 
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results. It should be noted that none of the available economic evaluations addressed the 
question relevant to health systems in lower income countries where the most likely available 
treatment is BSC. In fact, most Latin American countries do not have a reimbursement 
strategy in place for the use of SU or other MRCC targeted therapy, however many will 
consider exceptional mechanisms of access that lead to high expenditure and equity 
issues[40]. This is also consistent with the reality faced by some eastern European countries 
where, despite the incidence and mortality rates of kidney cancer are among the highest in the 
world, the access to first-line targeted therapies has been slow and has faced many 
obstacles[41].    
This study has some limitations. The model uses utilities reported in the literature that were 
mainly derived from Anglo-Saxon population. It is well-known that valuation methods like 
time trade off reflect population’s preferences that may not necessarily match with the 
Chilean population. Given the incremental health benefits (QALYs) obtained from this study 
are so small, the results are very sensitive to the source of utility used. However, given the 
lack of local utility data, values obtained from the British population were considered a 
reasonable alternative. In addition, the model assumption that treatment was immediately 
discontinued once progression was established, is also considered a limitation. In practice, 
this will depend on the time when the patient is assessed by the oncologist, which does not 
necessarily occur at the exact time of progression. This assumption may determine a bias that 
favors higher cost treatments like SU or PA. 
The main source of uncertainty originates from the reported OS treatment effect from the 
study that compares PA versus PL[15-17]. The latter is partly explained by the cross-over of 
patients who initially received PL and upon progression, received PA, positively impacting the 
OS of patients. In fact, without adjustment, the HR did not show statistically significant 
differences (HR OS 0.91; 95% CI 0.71-1.16: p=0.224). To account for this structural 
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uncertainty, the authors of this study provided two adjusted estimates obtained through two 
different methodologies, RPSFT and IPCW (inverse probability of censor weighting). However, 
both methods have advantages and disadvantages that increase the uncertainty in relation to 
this parameter. Despite this limitation, it is important to highlight that this parameter is useful 
and adequate from the perspective of an economic evaluation. The Bayesian statistical 
analysis, inherent to probabilistic sensitivity analysis, allows us to capture this uncertainty. 
Cost-effectiveness analysis have been used by most, if not all, countries that currently have an 
HTA agency (or equivalent government body) to assess whether the use of first line treatment 
with targeted therapies, like SU or PA, represent good value for money. MRCC is an interesting 
case study as positive recommendations have been given despite high ICERs, based on other 
social values, mainly that MRCC is a relatively rare cancer with few available treatment 
options[43]. In the UK, SU was the first drug recommended after the adoption of a new 
guidance in 2009 for end-of life drug appraisal, which enables access to drugs for incurable 
illnesses. In this guidance, NICE supports the use of certain treatments with an ICER outside 
the threshold range of £20,000 - £30,000/QALY, if the patient population is small and there is 
a sufficient increase in survival[44]. This is a contentious discussion in countries that have an 
established HTA process to support decision-making, especially where judgments about 
distributive justice provided by cost-effectiveness have an important role in the decision itself. 
Unlike most previous studies, our analysis is more conservative and very cautious when 
concluding which alternative is more cost-effective. In fact, our results highlight important 
parameter uncertainties and limited evidence to recommend one alternative versus the other. 
Important is to emphasize that our study is the first to additionally compare SU and PA versus 
BSC, the standard of care in Chile and most developing countries, which was only possible 
after conducting an MTC.  
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5 Conclusion 
The results show that neither SU nor PA are cost-effective alternatives compared to the 
standard strategy or BSC from the perspective of the Chilean public health care system. 
However, in the case there is a willingness to finance any of these alternatives, for example, 
because they are considered orphan drugs, high cost or MRCC becomes a public health 
priority, then the question is which of the two (PA or SU) represents a better use of public 
resources. Due to the low incremental health benefit observed and the high second order 
uncertainty, it is reasonable to address this question as a cost minimization exercise, which is 
mainly determined by the price of each alternative. 
6 Key issues  
• SU nor PA are cost-effective alternatives compared to the standard strategy or BSC from 
the perspective of the Chilean public health care system. 
• At a suggested threshold of 3 GDP per capita (approx. US$55,041), the probability of cost-
effectiveness of SU, PA and BSC was 42%, 39% and 19% respectively. This probability 
increases to 54%, 70% and an 82% when the SU price is reduced a 75%, 50% and 25% 
respectively. 
• The decision between SU or PA is highly sensitive to the price of the drugs, rather than the 
outcomes. 
• If there would be willingness to finance any of these alternatives, it is reasonable to 
address this issue as a cost minimization exercise, which is mainly determined by the price of 
each alternative. 
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Table and figure legends 
Figure legends 
Figure 1. Time-dependent Markov model to represent the natural history of MRCC  
Figure 1 represents the natural history of MRCC where patients transit through four possible 
health states: (1) patients receiving first-line treatment, (2) patients receiving second-line 
treatment, (3) patients receiving BSC and (4) specific-cause death.  
1. Probability of not progressing and remaining in 1st line treatment.  
2. Probability of death given patient received 1st line treatment.  
3. Probability of disease progression 
a. Probability of receiving 2nd line given 1st line treatment.  
b. Probability of receiving BSC given 1st line treatment.  
4. Probability of not progressing and remaining with second line treatment.  
5. Probability of disease progression given patient received 2nd line treatment.  
6. Probability of death given BSC. 
7. Probability of remaining in BSC.  
Abbreviations: BSC: best supportive care; MRCC: metastatic renal cell carcinoma 
 
Figure 2A: Mixed treatment comparison network for PFS.  
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Figure 2A represents the network for PFS consisting of five studies and five possible 
treatment alternatives for MRCC.  
 
Abbreviations: BE: bevacizumab; IFNα: interferon alpha; BSC: best supportive care; MRCC: 
metastatic renal cell carcinoma; PFS: progression free survival. 
NOTE: Dashed arrows represent indirect comparison and solid arrows represent direct 
compared evidence.  
Figure 2B: Mixed treatment comparison network for OS.  
Figure 2B represents the network for OS consisting of five studies and five possible treatment 
alternatives for MRCC.  
Abbreviations: BE: bevacizumab; IFNα: interferon alpha; BSC: best supportive care; MRCC: 
metastatic renal cell carcinoma; OS: overall survival. 
NOTE: Dashed arrows represent indirect comparison and solid arrows represent direct 
compared evidence.  
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Figure 3-A and 3-B: Probabilistic sensitivity analysis: cost-effectiveness plane 
Figure 3-A and 3-B represent the probabilistic sensitivity analysis for the base case and price 
reduction scenario for SU versus PA and PA versus BSC. Each dot represents 1 iteration of the 
model. Y-axis represents incremental costs. X-axis represents incremental QALYs. Diagonal 
lines represent the cost-effectiveness thresholds of 1 and 3 GDP per capita. Figure 3-B 
assumes the price of SU and PA were reduced 75% relative to the base case price.  
Abbreviations: BSC: best supportive care; GDP, gross domestic product; ICER: incremental 
cost-effectiveness ratio; PA, pazopanib; QALYs, quality adjusted life years; USD, US dollars; SU, 
sunitinib; vs: versus.  
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Figure 4-A and 4-B: Probabilistic sensitivity analysis: acceptability curve 
Figure 3-A and 3-B represent the probabilistic sensitivity analysis for the base case and price 
reduction scenario for SU versus PA and PA versus BSC. Vertical lines represent the cost-
effectiveness thresholds of 1 and 3 GDP per capita. Y-axis represents the probability the 
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intervention is cost-effective. X-axis represents possible thresholds. Figure 3-B assumes the 
price of SU and PA were reduced 75% relative to the base case price.  
Abbreviations: BSC: best supportive care; GDP, gross domestic product; PA, pazopanib; 
QALYs, quality adjusted life years; USD, US dollars; SU, sunitinib; vs: versus.  
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Table legends 
Table 1. Base line scenario: model input parameters and assumptions 
Abbreviations: BSC: best supportive care; HR: hazard ratio; IFN: interferon; IPD: individual 
patient data; mg; milligrams; N/A: not applicable; PA: pazopanib; PL: placebo; RPSFT: Rank 
Preserving Structural Failure Time; SU: sunitinib.  
Table 2: Results of the indirect treatment comparison for the PFS and OS hazard ratio of 
all possible MRCC treatments. 
Abbreviations: BE/IFNα: bevacizumab plus interferon alpha; BCI: Bayesian credibility 
interval; BSC: best supportive care; HR: hazard ratio, IFNα: interferon alpha; PA: pazopanib; 
SU: sunitinib; vs: versus. 
Table 3: Expected cost per cycle (6 weeks) and category for each "First line" and 
"second line" treatment in 2015 US dollars 
Abbreviations: BSC: best supportive care. 
NOTE: 1The average expected cost considers laboratory tests, mental health, medical 
procedures, hospitalization, images, medical supplies and medical visits with a specialist. 
Table 4: Cost effectiveness results: incremental analysis of sunitinib versus pazopanib 
and BSC as first line treatments for the base case and price reduction scenario.  
Abbreviations: BSC: best supportive care; ICER: incremental cost effectiveness ratio; Inc: 
incremental; PA: pazopanib, QALY: quality adjusted life years; SU: sunitinib; TX: treatment. 
NOTE: treatment price reduction were relative to the published list price. 
Table 5: Cost effectiveness results: scenario analysis assuming 50% of patients were 
given second line treatment.  
Abbreviations: BSC: best supportive care; ICER: incremental cost effectiveness ratio; Inc: 
incremental; TX: treatment; PA: pazopanib; QALY: quality adjusted life years; SU: sunitinib. 
 
 
 
